Carter-Wallace DESI hearings
FDA on June 5 granted firm's request to hold a hearing on an agency proposal to withdraw the NDA for the antihypertensive Diutensen (cryptenamine with methyclothiazide). A prehearing conference has been scheduled for Sept. 25. Also on June 5, FDA agreed to hold a similar hearing on the antidepressant Deprol (meprobamate with benactyzine). A prehearing conference date has not yet been set.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”